Journal of Drugs in Dermatology最新文献_第4页

Artificial Intelligence-Based Personalization of Treatment Regimen for Hair Loss: A 6-Month Clinical Trial. 基于人工智能的脱发个性化治疗方案：为期6个月的临床试验

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8611

Vinay Bhardwaj, Nancy Rodgers, Oded Harth, Yoram Harth

{"title":"Artificial Intelligence-Based Personalization of Treatment Regimen for Hair Loss: A 6-Month Clinical Trial.","authors":"Vinay Bhardwaj, Nancy Rodgers, Oded Harth, Yoram Harth","doi":"10.36849/JDD.8611","DOIUrl":"https://doi.org/10.36849/JDD.8611","url":null,"abstract":"Hair loss affects up to 50% of women and 80% of men. The high costs and wait times for professional consultations lead many to seek one-size-fits-all solutions that are frequently ineffective. This study tested an artificial intelligence (AI) model for customizing non-medicated hair loss treatments. In a 24-week trial, 38 women with self-reported hair thinning received personalized product kits based on AI analysis of scalp images and questionnaires. Treatments included various combinations of topical serums, shampoos, oral supplements, and marine collagen peptides. Of the 27 participants who completed the study, significant improvements were observed in hair growth, coverage, and thickness (P<0.001 for all). Hair shedding decreased by 37.3% at 12 weeks and 32.4% at 24 weeks. Scalp transepidermal water loss was reduced by 61.5% at 12 weeks and 69% at 24 weeks. Scanning electron microscopy showed improved hair texture. Participants reported overall hair improvement (88.9%), better scalp health (85.2%), and less hair brittleness (92.6%) (P<0.001 for all). No adverse events were reported. The AI-driven platform effectively delivered personalized hair loss treatments, suggesting a data-driven, customized, and accessible self-served alternative for hair loss management. J Drugs Dermatol. 2025;24(3):233-238. doi:10.36849/JDD.8611.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"233-238"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FULL SUPPLEMENT: Exploring The Scalp Barrier and Microbiome In Diverse Dandruff Patients. 全面补充：探索头皮屏障和微生物组在不同的头皮屑患者。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.32730

E T Al

引用次数: 0

Management of Acute Hematomas and Methods to Mitigate Risk. 急性血肿的处理和降低风险的方法。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8453

Vixey Silva, Cassandra Johnson, Lisa Fronek, Richard Miller

引用次数: 0

Comparative Efficacy of Intralesional Steroid Injections vs Cryotherapy for the Treatment of Alopecia Areata. 病灶内类固醇注射与冷冻治疗斑秃的疗效比较。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8499

Seemal Akram, Isabella J Tan, Rohan R Shah, Zainab Tariq, Hassan Javaid, Babar Rao

{"title":"Comparative Efficacy of Intralesional Steroid Injections vs Cryotherapy for the Treatment of Alopecia Areata.","authors":"Seemal Akram, Isabella J Tan, Rohan R Shah, Zainab Tariq, Hassan Javaid, Babar Rao","doi":"10.36849/JDD.8499","DOIUrl":"https://doi.org/10.36849/JDD.8499","url":null,"abstract":"Introduction: The precise etiology of alopecia areata (AA) remains unclear. Various treatments, including corticosteroids, minoxidil, immunotherapy, and phototherapy, have shown varying efficacy. Injectable corticosteroids, despite being invasive, are the first-line treatment, while topical steroids are also commonly used.Objective: To compare the efficacy of intralesional steroid (triamcinolone acetate) versus cryotherapy for the treatment of alopecia areata over a 6-month period in the Department of Dermatology at the Pakistan Atomic Energy Commission General Hospital.Methods: The study included 118 patients (aged 15 to 50 years, both genders) with a single patch of alopecia areata on the scalp. Exclusion criteria included active secondary infections, cold intolerance, multiple patches, iatrogenic or primary immunosuppression, pregnancy, or breastfeeding. Patients were randomly assigned to two groups: Group A received intralesional steroid injections, and Group B underwent cryotherapy with liquid nitrogen. Treatment efficacy was then evaluated.Results: The mean age was 27.78 +/- 4.68 years in Group A and 26.63 +/- 4.91 years in Group B. Most patients (95, 80.51%) were aged 15 to 30 years. Males predominated with 86 (72.27%) participants, resulting in a male-to-female ratio of 2.6:1. The mean duration of alopecia areata was similar in Group A (8.51 +/- 3.94 months) and Group B (8.39 +/- 3.13 months). Group A (intralesional corticosteroids) had a significantly higher efficacy rate, with 49 patients (83.05%) responding positively, compared to 30 patients (50.85%) in Group B (cryotherapy) (P=0.0001), as shown in Table 1.Conclusion: The study concluded that the efficacy of intralesional steroids may be superior to cryotherapy for the treatment of alopecia areata. J Drugs Dermatol. 2025;24(3):294-297. doi:10.36849/JDD.8499.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"294-297"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares. Spesolimab治疗广泛性脓疱性银屑病。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8322

Sabine L Abukhadra, Shirley P Parraga, Steven R Feldman

{"title":"Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares.","authors":"Sabine L Abukhadra, Shirley P Parraga, Steven R Feldman","doi":"10.36849/JDD.8322","DOIUrl":"https://doi.org/10.36849/JDD.8322","url":null,"abstract":"Background: Generalized pustular psoriasis (GPP) is a rare, life-threatening neutrophilic skin condition characterized by widespread sterile eruptions. Treatment approaches vary due to a lack of standardized guidelines. Interleukin-36 signaling is involved in GPP activation and disease progression. An interleukin-36 receptor monoclonal antibody, spesolimab, is a new treatment option for GPP flares. The Effisayil 1 clinical trial investigated the efficacy and safety of spesolimab, a remarkable task due to the unpredictable nature of GPP flares coupled with intrinsic trial challenges.Methods: We searched PubMed using the terms: generalized pustular psoriasis, spesolimab, and Effisayil 1.Clinicaltrials: gov was used to identify clinical trial data including efficacy, safety, and tolerability.Results: In Effisayil 1, a phase II study, 53 patients with a GPP flare were enrolled: 35 patients were randomized to spesolimab and 18 to placebo. At baseline, 46% of the patients in the spesolimab group and 39% of the patients in the placebo group had a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 3; 37% and 33% of patients in each group, respectively, had a pustulation subscore 4. At the end of week 1, 19 of the patients in the spesolimab group, (54.3%) had a pustulation subscore of 0 compared to 1 patient in the placebo group (5.6%) (-49%, P<0.001).Conclusions: The Effisayil 1 trial faced many difficulties affecting trial completion, but the results of this study provided encouraging results. Spesolimab was effective in treating GPP flares after just one week. Patient demographics and baseline characteristics did not affect the efficacy or safety profile of spesolimab. J Drugs Dermatol. 2025;24(3):242-245. doi:10.36849/JDD.8322.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"242-245"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alopecia as an Adverse Event of Immune Checkpoint Inhibitor Therapies: Clinical Evidence and Outcomes. 作为免疫检查点抑制剂疗法不良反应的脱发：临床证据和结果。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.7828

Minjun Park, Susie Suh, Colin Kincaid, Katerina Yale, Natasha Atanaskova Mesinkovska

{"title":"Alopecia as an Adverse Event of Immune Checkpoint Inhibitor Therapies: Clinical Evidence and Outcomes.","authors":"Minjun Park, Susie Suh, Colin Kincaid, Katerina Yale, Natasha Atanaskova Mesinkovska","doi":"10.36849/JDD.7828","DOIUrl":"https://doi.org/10.36849/JDD.7828","url":null,"abstract":"Immunotherapy utilizing immune checkpoint inhibitors (ICIs) such as PD-1, PD-L1, and CTLA-4 inhibitors has revolutionized cancer therapy by enhancing T cell recognition and attack against cancer cells.1 Immune-related adverse events (irAEs) are a limitation of ICI therapy, encompassing various manifestations such as colitis and cutaneous adverse events such as dermatitis, alopecia, and vitiligo.2 Hair loss is a common concern of cancer patients as they embark on their therapeutic paths. The evidence on alopecia from isolated clinical trials with ICI therapies is limited and largely lacks diagnostic and prognostic details to help guide patients.3,4 In this systematic review, we examined the types of alopecia as part of the irAEs of ICI therapy, timing of onset, prognosis, and treatment approaches. Our analysis includes 19 studies describing new-onset non-scarring or scarring alopecia following ICI treatment. Alopecia was a rare adverse event in the setting of ICIs (n=26) with the onset of alopecia occurring within one year of initiating treatment. Slightly over half of the affected patients reported some degree of hair regrowth after attempted alopecia-directed treatments. We discuss available data to increase awareness of this rare but potentially permanent side effect of ICI therapy. Further research is warranted to enhance our understanding of alopecia as an irAE and to optimize patient management strategies. J Drugs Dermatol. 2025;24(3):255-260. doi:10.36849/JDD.7828.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"255-260"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disparities in Alopecia Areata and Vitiligo FDA-Approved Therapies in Medicaid Formularies. 斑秃和白癜风在医疗补助处方中fda批准的治疗方法的差异。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01

Apoorva Mehta, Nikhita Perry, Iain Encarnacion, Nicholas Mollanazar, Susan C Taylor

引用次数: 0

INDIVIDUAL ARTICLE: NECOM 5: Algorithm for the Treatment and Supportive Management of Targeted Therapy-Related Cutaneous Adverse Events. 个别文章：NECOM 5：靶向治疗相关皮肤不良事件的治疗和支持管理算法。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.88541

Ada Girnita, Peter Bjerring, Gabriela Lladó Grove, Samsa Kauppi, Anneke Andriessen, Charles Lynde, Andreas Stensvold

{"title":"INDIVIDUAL ARTICLE: NECOM 5: Algorithm for the Treatment and Supportive Management of Targeted Therapy-Related Cutaneous Adverse Events.","authors":"Ada Girnita, Peter Bjerring, Gabriela Lladó Grove, Samsa Kauppi, Anneke Andriessen, Charles Lynde, Andreas Stensvold","doi":"10.36849/JDD.88541","DOIUrl":"https://doi.org/10.36849/JDD.88541","url":null,"abstract":"Background: The cancer burden in the Nordic European countries remains substantial, but new treatment approaches, such as targeted therapy, have increased the survival of cancer patients. During and following cancer treatment regimens, however, patients' quality of life may be severely affected by sequelae, including cutaneous adverse events (cAEs). Overall, practical clinical tools for the management of cAEs in cancer patients and survivors have been lacking.Methods: The Nordic European Cutaneous Oncodermatology Management (NECOM) project addresses cAEs in cancer patients, aiming to identify specific challenges and develop practical algorithms for their management. NECOM 1 and 2 provided an overview of cAEs and general recommendations for prevention and appropriate skin care regimens. NECOM 3 and 4 explored cAEs related to radiation therapy and immunotherapy, respectively. This NECOM 5 develops a practical algorithm for preventing and treating targeted therapy-related cAEs (TTcAEs).Results: The NECOM panel discussed the findings of a systematic review of cAEs associated with targeted cancer therapy. The panel reached a consensus on a practical algorithm for TTcAEs, considering the current evidence, expert opinion, and clinical settings in the Nordic countries. The algorithm included general prevention and skin care recommendations, followed by specific advice for addressing the most common TTcAEs (papulopustular eruption, pruritus, hand-foot skin reaction, and paronychia).Conclusions: Targeted therapy-related cAEs may negatively affect cancer patients and survivors. The NECOM panel provides a practical algorithm for preventing and managing TTcAEs to improve cancer patient outcomes and quality of life. J Drugs Dermatol. 2025;24:3(Suppl 2):s3-10.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"88541s3-88541s10"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Healing of Mohs Surgery Wounds on the Vermilion and Cutaneous Lip With Bovine Collagen Dressings. 牛胶原蛋白敷料对红唇及皮唇莫氏手术创面愈合的影响。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.8570

Emilie Jacobsen, Joanna Dong, C William Hanke

{"title":"Healing of Mohs Surgery Wounds on the Vermilion and Cutaneous Lip With Bovine Collagen Dressings.","authors":"Emilie Jacobsen, Joanna Dong, C William Hanke","doi":"10.36849/JDD.8570","DOIUrl":"https://doi.org/10.36849/JDD.8570","url":null,"abstract":"Background: Surgical wounds confined to the vermilion lip and superficial orbicularis musculature can be allowed to heal by second intention with good aesthetic and functional results. Historically, defects extending onto the cutaneous lip or into the deeper orbicularis musculature have generally required more extensive repairs with local flaps to avoid cosmetic distortion or functional issues. We aim to demonstrate the utility of bovine collagen xenografts to augment second intention healing of surgical defects on the lip, including those defects extending into the cutaneous lip and musculature.Type of study: Retrospective observational study with historical control.Results: Twenty-nine patients with 31 tumors underwent Mohs surgery on the lip, with most wounds extending into the orbicularis oris musculature (65%) and onto the cutaneous lip (65%). The average defect size was 2.8 cm2 (range, 0.7-6.3 cm2). The average time to re-epithelialization was 29.7 days, with a rate of 10.2 days per cm2 of defect size, which was faster than historical controls of second-intention healing. Cosmetic outcomes were rated as acceptable to outstanding in 92% of cases.Conclusion: For wounds on the vermilion lip, including those extending onto the cutaneous lip and into the orbicularis musculature, bovine collagen xenografts are an effective adjunct to second-intention healing with good cosmetic and functional outcomes. J Drugs Dermatol. 2025;24(3):270-274. doi:10.36849/JDD.8570.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"270-274"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Concurrent Lichen Planopilaris and Female Androgenic Alopecia in Skin of Color: A Case Series. 并发扁平毛癣和女性雄激素性脱发的皮肤颜色：一个案例系列。

IF 1.5 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI: 10.36849/JDD.7318

Eliza Balazic, Hailey Konisky, Eden Axler, Kseniya Kobets

{"title":"Concurrent Lichen Planopilaris and Female Androgenic Alopecia in Skin of Color: A Case Series.","authors":"Eliza Balazic, Hailey Konisky, Eden Axler, Kseniya Kobets","doi":"10.36849/JDD.7318","DOIUrl":"https://doi.org/10.36849/JDD.7318","url":null,"abstract":"Background: Trichoscopy findings can differ in the skin of color requiring a dedicated approach with adequate examination in order to ensure proper diagnosis and treatment. This case series details three cases of concurrent lichen planopilaris (LPP) and female androgenic alopecia (FAGA) in the skin of color.Methods: Gross examination of all cases revealed mild to moderate hair density thinning of the temporal and frontal scalp. Trichoscopy was done in all three cases before biopsy. The temporal scalp of each patient showed diffuse hair follicle miniaturization with minimal terminal hairs and brown follicular halos, all findings were consistent with FAGA. However, upon inspection of the frontal scalp, each case revealed findings associated with scarring alopecia including scale, erythema, and peripilar casts in addition to the presence of follicle miniaturization.Results: In the first two cases, two punch biopsies were taken, one from the temporal scalp and one from the frontal scalp. Temporal biopsy revealed FAGA and frontal biopsy revealed LPP arising in a background of AGA. In the third case, only the frontal scalp was biopsied, which showed LPP in a background of FAGA. All three cases received the same treatment regimen; clobetasol 0.05% solution and minoxidil 5% foam/solution topically for treatment of FAGA and monthly intralesional triamcinolone acetonide for treatment of the LPP.Conclusion: Our report suggests the importance of total scalp dermoscopy and the need for biopsies in areas with varying dermoscopy findings as opposed to areas with the most significant hair loss. J Drugs Dermatol. 2025;24(3):320-322. doi:10.36849/JDD.7318.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"320-322"},"PeriodicalIF":1.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0